Cochrane · systematic review · CD013091
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review
Atakpa, EC, Thorat, MA, Cuzick, J, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 62.5%Low 3 · 37.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Prognostic biomarker ‐ treatment studies
Population: women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Breast cancer mortality ‐ tamoxifen | no estimate extracted | 1 study · 97 participants | Low |
Recurrence ‐ tamoxifen | no estimate extracted | 2 studies · 1956 participants | Very low Downgraded: risk of bias, imprecision |
Recurrence ‐ AIs | no estimate extracted | 1 study · 175 participants | Very low Downgraded: risk of bias, imprecision |
Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) | no estimate extracted | 1 study · 284 participants | Very low Downgraded: risk of bias, imprecision |
Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) | no estimate extracted | 1 study · 284 participants | Very low Downgraded: risk of bias, imprecision |
Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) | no estimate extracted | 1 study · 87 participants | Very low Downgraded: risk of bias, imprecision |
Prognostic biomarker ‐ prevention studies
Population: women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Incidence of invasive breast cancer and DCIS ‐ tamoxifen | no estimate extracted | 1 study · 51 participants | Low Downgraded: risk of bias |
Predictive biomarker
Population: women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor) or not receiving endocrine therapy (control group)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prevention: incidence of invasive breast cancer and DCIS ‐ tamoxifen | no estimate extracted | 1 study · 123 participants | Low Downgraded: imprecision |